MyLymphomaTeam

Brukinsa (zanubrutinib) is a BTK inhibitor medication typically taken as a pill once or twice daily. It's approved to treat several types of non-Hodgkin lymphoma, including mantle cell lymphoma, Waldenstrom's macroglobulinemia, and certain cases of follicular lymphoma. Common side effects include fatigue, bruising Show Full Answer

Brukinsa (zanubrutinib) is a BTK inhibitor medication typically taken as a pill once or twice daily. It's approved to treat several types of non-Hodgkin lymphoma, including mantle cell lymphoma, Waldenstrom's macroglobulinemia, and certain cases of follicular lymphoma. Common side effects include fatigue, bruising, diarrhea, cough, and anemia. Some people may experience neutropenia (low white blood cell counts) and skin rashes. More serious but rare side effects can include hemorrhage, infections, irregular heartbeat, and liver problems. It's important to note that Brukinsa can also increase the risk of secondary cancers, including skin carcinomas.

If you're pregnant or planning to become pregnant, you should discuss this with your healthcare provider as Brukinsa may harm an unborn baby. While specific remission timelines aren't mentioned in the provided sources, it's recommended to maintain regular contact with your oncology team to monitor your response to treatment. They can assess your progress through various tests and adjust your treatment plan as needed.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Oral Treatments vs. Chemotherapy for Indolent Non-Hodgkin Lymphoma (NHL)

Waldenstrom’s Macroglobulinemia: An Overview